Atom – LifeCareNews

LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283

Atom Bioscience Announces Positive Results of Phase 2a China Clinical Trial of Its URAT1 Inhibitor…

The China study confirms a Phase 2a trial in Australia demonstrating ABP-671 significantly reduces serum uric acid levels and is well tolerated JIANGSU, China--(BUSINESS WIRE)--Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical…

Atom Bioscience to Present Final Data from its Positive Phase 2a Clinical Trial in Chronic Gout at…

ABP-671 effective at lowering serum uric acid, the cause of gout JIANGSU, China--(BUSINESS WIRE)--Atom Bioscience, a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced…